MX2022001676A - Particulas virales para uso en el tratamiento de sinucleinopatias tal como enfermedad de parkinson mediante terapia genica. - Google Patents

Particulas virales para uso en el tratamiento de sinucleinopatias tal como enfermedad de parkinson mediante terapia genica.

Info

Publication number
MX2022001676A
MX2022001676A MX2022001676A MX2022001676A MX2022001676A MX 2022001676 A MX2022001676 A MX 2022001676A MX 2022001676 A MX2022001676 A MX 2022001676A MX 2022001676 A MX2022001676 A MX 2022001676A MX 2022001676 A MX2022001676 A MX 2022001676A
Authority
MX
Mexico
Prior art keywords
treatment
gene therapy
disease
parkinson
viral particles
Prior art date
Application number
MX2022001676A
Other languages
English (en)
Spanish (es)
Inventor
Ralph Michael Linden
Aseguinolaza Gloria Gonzalez
Perez José Luis Lanciego
Original Assignee
Fundacion Para La Investig Medica Aplicada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67659024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022001676(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundacion Para La Investig Medica Aplicada filed Critical Fundacion Para La Investig Medica Aplicada
Publication of MX2022001676A publication Critical patent/MX2022001676A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01062—Glycosylceramidase (3.2.1.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
MX2022001676A 2019-08-12 2020-08-06 Particulas virales para uso en el tratamiento de sinucleinopatias tal como enfermedad de parkinson mediante terapia genica. MX2022001676A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382706 2019-08-12
PCT/EP2020/072087 WO2021028299A1 (en) 2019-08-12 2020-08-06 Viral particles for use in treating synucleinopathies such as parkinson's diseases by gene therapy

Publications (1)

Publication Number Publication Date
MX2022001676A true MX2022001676A (es) 2022-05-03

Family

ID=67659024

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001676A MX2022001676A (es) 2019-08-12 2020-08-06 Particulas virales para uso en el tratamiento de sinucleinopatias tal como enfermedad de parkinson mediante terapia genica.

Country Status (18)

Country Link
US (1) US20220298528A1 (cg-RX-API-DMAC7.html)
EP (1) EP4013437A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023500011A (cg-RX-API-DMAC7.html)
KR (1) KR20220099944A (cg-RX-API-DMAC7.html)
CN (1) CN114786694A (cg-RX-API-DMAC7.html)
AR (1) AR119609A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020328827A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022002615A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149844A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000292A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001192A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22008949A (cg-RX-API-DMAC7.html)
IL (1) IL290357A (cg-RX-API-DMAC7.html)
MX (1) MX2022001676A (cg-RX-API-DMAC7.html)
PE (1) PE20220601A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550282A1 (cg-RX-API-DMAC7.html)
TW (1) TW202120687A (cg-RX-API-DMAC7.html)
WO (1) WO2021028299A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113795575A (zh) 2019-02-04 2021-12-14 自由行疗法有限公司 多核苷酸
CA3181024A1 (en) * 2020-08-06 2022-02-10 Fundacion Para La Investigacion Medica Aplicada Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy
JP2025516136A (ja) * 2022-04-19 2025-05-27 シャンハイ ヴァイタルゲン バイオファーマ カンパニー リミテッド 神経変性疾患の治療のための組み換えaavベクター
CN121406674A (zh) * 2022-10-08 2026-01-27 凌意(杭州)生物科技有限公司 用于治疗GCase缺乏相关疾病的多核苷酸
KR20250046126A (ko) * 2023-09-22 2025-04-02 주식회사 스탠드업테라퓨티스 신규한 파킨슨 병 치료제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985235A1 (en) * 2015-05-07 2016-11-10 Shire Human Genetic Therapies, Inc. Glucocerebrosidase gene therapy for parkinson's disease
CN111542549A (zh) * 2017-10-03 2020-08-14 普利维尔治疗公司 用于溶酶体障碍的基因疗法
WO2019068854A1 (en) * 2017-10-06 2019-04-11 Ospedale San Raffaele S.R.L. GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS

Also Published As

Publication number Publication date
AR119609A1 (es) 2021-12-29
CO2022001192A2 (es) 2022-07-19
BR112022002615A2 (pt) 2022-05-03
TW202120687A (zh) 2021-06-01
US20220298528A1 (en) 2022-09-22
PH12022550282A1 (en) 2022-11-21
KR20220099944A (ko) 2022-07-14
WO2021028299A1 (en) 2021-02-18
EP4013437A1 (en) 2022-06-22
ECSP22008949A (es) 2022-03-31
CA3149844A1 (en) 2021-02-18
CN114786694A (zh) 2022-07-22
AU2020328827A1 (en) 2022-03-03
IL290357A (en) 2022-04-01
JP2023500011A (ja) 2023-01-04
PE20220601A1 (es) 2022-04-25
CL2022000292A1 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
ECSP22008949A (es) Partículas virales para uso en el tratamiento de sinucleinopatías tal como enfermedad de parkinson mediante terapia génica
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
MX2021012184A (es) Terapias genicas para trastornos lisosomales.
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
WO2017191274A3 (en) Rna encoding a therapeutic protein
SA516380328B1 (ar) مركبات مستبدلة-8،6-دايوكسابيسيكلو[3-2-1]أوكتان-3،2-دايول asgpr كعوامل استهداف
EP4349404A3 (en) Respiratory virus vaccines
MX2018012880A (es) Metodos para proporcionar arn de hebra sencilla.
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
MX2020004005A (es) Terapias genicas para los trastornos lisosomales.
UY32629A (es) Compuestos antivirales, composiciones y uso para la manufactura de un medicamento para el tratamiento de trastornos asociados con hepatitis c.
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX339704B (es) Una formulacion homeopatica.
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
ECSP10010287A (es) Vectores de virus oncolíticos de viruela
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
BR112018017077A2 (pt) terapias de combinação para tratamento de atrofia muscular espinhal
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
BR112015018047A2 (pt) composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão
CL2017002304A1 (es) Métodos para tratar enfermedades
MX2018006636A (es) Fosfatos ciclicos y fosforoamidatos ciclicos para el tratamiento de trastornos neurologicos.
CL2011002617A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros.